These early changes show the medication is working, even before weight loss appears
Table of Contents: Is Oral Semaglutide FDA-Approved for Weight Loss
HS induces S-sulfhydration of MuRF1 at the Cys44 site, inhibiting its E3 ligase activity, reducing SERCA2a ubiquitination and degradation, thereby restoring SERCA2a function, lowering intracellular Ca 2+ , and enhancing contractile performance (Peng et al., 2022)
These studies will provide valuable insights into the long-term efficacy, safety, and tolerability of this triple-hormone receptor agonist, as well as its potential impact on cardiovascular outcomes
Singer , Senior Fellow, Cato Institute Tracy Zvenyach , Director, Policy Strategy & Alliances, Obesity Action Coalition 3:50 | Audience Q&A 4:25 | Closing Remarks 4:30 | Adjourn Health in the Headlines This event is part of the National Academy of Medicines Health in the Headlines series, which investigates high-profile health and health policy topics making the news
Unlike endogenous GLP-1, which is rapidly degraded by dipeptidyl peptidase-4, GLP-1 receptor agonists are resistant to degradation and have longer half-lives, particularly for modern long-acting agents, such as liraglutide, dulaglutide, semaglutide and tirzepatide